The Effect of Medication-related Support on the Quality of Life of Patients with Vasculitis in Relapse and Remission by CARPENTER, D. M. et al.
The Effect of Medication-related Support on the Quality of Life of
Patients with Vasculitis in Relapse and Remission
DELESHA M. CARPENTER, PhD, MSPH [Postdoctoral Fellow],
UNC Thurston Arthritis Research Center, University of North Carolina (UNC) Thurston Arthritis
Research Center, Chapel Hill, North Carolina, USA
JESSICA A. KADIS, MPH [Doctoral Student],
University of North Carolina (UNC) Thurston Arthritis Research Center, Chapel Hill, North
Carolina, USA
ROBERT F. DEVELLIS, PhD [Research Professor],
UNC Department of Health Behavior and Health Education, University of North Carolina (UNC)
Thurston Arthritis Research Center, Chapel Hill, North Carolina, USA
SUSAN L. HOGAN, PhD [Research Associate Professor], and
UNC Kidney Center, University of North Carolina (UNC) Thurston Arthritis Research Center,
Chapel Hill, North Carolina, USA
JOANNE M. JORDAN, MD [Director]
UNC Thurston Arthritis Research Center, University of North Carolina (UNC) Thurston Arthritis
Research Center, Chapel Hill, North Carolina, USA
Abstract
Objective—Few studies have investigated whether the utility of social support for patients with a
relapsing, remitting illness varies by activity level of the disease. Our goal was to determine
whether disease status (relapse vs remission) moderates the effect of medication-related support
from physicians and partners on the health-related quality of life (HRQOL) of patients with
vasculitis.
Methods—Patients with vasculitis (n = 228) completed baseline measures of disease status and
medication-related support and a 3-month followup measure of HRQOL (RAND 36-item health
survey 1.0). We calculated 8 HRQOL dimensions: physical functioning, physical role limitations,
bodily pain, general health, vitality, social functioning, emotional role limitations, and mental
health. Bonferroni-corrected t tests compared the HRQOL of patients in relapse to patients in
remission, and multivariate analysis of covariance determined whether disease status moderated
the effect of medication-related support from physicians and partners on patient HRQOL. Wilks’
lambda assessed whether the support-by-disease status interaction terms were significant.
Results—Relapsing patients reported significantly worse quality of life compared with
nonrelapsing patients for every HRQOL dimension except physical role limitations. Disease status
did not moderate the effect of physician (lambda = 0.48; p = 0.86) or partner (lambda = 1.51; p =
0.16) medication-related support on HRQOL, although greater physician and partner support
predicted better HRQOL for all dimensions except bodily pain and vitality.
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Conclusion—Vasculitis patients experience compromised HRQOL but the magnitude of the
compromise is greater for patients experiencing a relapse. Medication-related support from
physicians and partners is beneficial for patients’ HRQOL regardless of disease status.
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Over the past 40 years, the advent of more effective drug regimens has transformed
vasculitis from a frequently fatal, acute disease to a chronic condition with relapsing and
remitting episodes. Despite treatment with remission maintenance regimens, 30% to 60% of
vasculitis patients will experience a relapse, potentially causing organ damage,
hospitalization, or death1,2,3.
Similar to other chronic diseases, vasculitis has negative effects on patients’ physical and
mental health, including decreased physical functioning and increased
depression4,5,6,7,8,9,10,11,12,13. Beyond reductions in health-related quality of life (HRQOL),
patients often experience other negative sequelae. For example, the unpredictable course of
relapse and remission can cause patients to miss up to 6 consecutive weeks of work, leading
to financial strain5,7,14.
Although research has shown that vasculitis patients in remission report worse HRQOL than
healthy controls4, little is known about whether relapses further compromise patients’
HRQOL. Moreover, we are unaware of any published studies that have investigated whether
medication-related support affects the HRQOL of vasculitis patients in relapse and
remission differently. Studies of other chronic diseases consistently demonstrate that more
social support is associated with better physical and mental health outcomes15,16, and that
partners16,17,18,19,20 and physicians21,22,23,24 are important sources of emotional and
informational support for patients.
Using longitudinal data, we attempted to address the research gaps described above by
comparing 8 domains of HRQOL for vasculitis patients in relapse and remission. We also
examined whether disease status, defined as relapse versus remission, moderated the effect
of medication-related social support from physicians and partners on patients’ HRQOL.
MATERIALS AND METHODS
All data were collected as part of the Accessing Social Support in Symptom Treatment
(ASSIST) Study, which evaluated the level of support of vasculitis patients’ social networks,
especially with regard to medication management. The ASSIST Study consisted of 2 online
questionnaires administered 3 months apart. Eligible patients had a self-reported diagnosis
of vasculitis, were at least 18 years of age, were able to read and write in English, had
Internet access, and were taking at least one medication to treat their vasculitis. This study
was approved by the Institutional Review Board at the University of North Carolina at
Chapel Hill.
Sample
We recruited 106 participants for the ASSIST Study by distributing study information to
attendees at a vasculitis patient conference (n = 39) and mailing to physician-diagnosed
vasculitis patients who were part of the Glomerular Disease Collaborative Network (n = 38)
and previous vasculitis studies (n = 29). We also contacted members of vasculitis support
groups and posted announcements on vasculitis websites, in patient newsletters, and on
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patient list-serves, which yielded 147 eligible and interested participants. Carpenter and
colleagues provide a thorough description of recruitment procedures25.
Of the 253 eligible patients, 232 (91.7%) completed the 1-hour baseline questionnaire.
Reasons for noncompletion included never responding to study correspondence (n = 7),
technical issues (n = 7), or being too sick (n = 4) or too busy (n = 3) to participate.
Compared with completers, non-completers were not significantly different in terms of
gender or self-reported vasculitis type.
Only 4 of the 232 participants were lost to followup for the second questionnaire, resulting
in a response rate of 98.2%. Participants who completed both questionnaires received a $10
gift card.
Measures
The baseline survey contained measures of physician support, partner support, disease
status, and sociodemographic variables. The 3-month followup questionnaire contained the
HRQOL measure.
Physician and partner medication-related support
Participants completed 4 items about perceived medication-related adherence support from
their primary vasculitis physician (α = 0.80) and their partner (α = 0.79). Specifically,
participants indicated how often their physician or partner supported them in taking their
vasculitis medications, shared new information about vasculitis medicines, provided helpful
hints about how to deal with the medication side effects, and provided enough support for
taking their medications as prescribed. Response options ranged from 1 = “does not do this”
to 4 = “does this a lot.” Responses of “not applicable” were recoded as “1” to indicate that
the physician or partner did not provide that type of support. We created a summary score by
averaging the 4 items; higher scores (range of 1–4) reflected more support.
Disease status
Participants reported their disease status as “currently experiencing a flare/relapse” or “not
currently experiencing a flare/relapse.”
Sociodemographics
Participants answered one item each about gender, race (white vs non-white), age, education
(in years), year of vasculitis diagnosis, health insurance status (insured vs not insured), and
vasculitis type [antineutrophil cytoplasmic autoantibody (ANCA)-associated granulomatous
vasculitis vs other].
Health-related quality of life
We used the RAND 36-item health survey v 1.0 to assess HRQOL26. The measure assesses
8 domains of HRQOL, including physical functioning (10 items, α = 0.93), bodily pain (2
items, α = 0.91), role limitations due to physical health (4 items, α = 0.88), role limitations
due to emotional health (3 items, α = 0.87), mental health (5 items, α = 0.85), social
functioning (2 items, α = 0.90), vitality (4 items, α = 0.91), and general health perceptions
(5 items, α = 0.82). For all subscales, higher scores correspond to better HRQOL.
For the multiple-item scales described above, summary scores were treated as missing if
more than 25% of the scale items were missing.
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All analyses were conducted using SAS v 9.2. We converted the HRQOL subscale scores to
norm-based scores using procedures described by Ware and Kosinski27. Norm-based
HRQOL scores indicate how the population of interest scored with respect to the general
1998 US population (score = 50). For this study, we provided age-adjusted HRQOL
comparisons by comparing norm-based HRQOL scores for patients in relapse and remission
to norm-based scores for the general US population aged 54–65 years (i.e., age group
corresponding to the mean age of our patient sample). Bonferroni-corrected independent
sample t tests (α = 0.05/8 or 0.00625) were used to determine whether patients experiencing
a relapse differed from patients in remission for each of the 8 domains.
To investigate whether disease status moderated the effect of physician and partner support
on HRQOL, we created 2 interaction terms: disease status-by-physician support and disease
status-by-partner support. We then ran 2 separate multivariate analysis of covariance
(MANCOVA) models looking at the effects of physician support and partner support on
patient HRQOL. We chose to investigate the effects of physician and partner support
independently because they were moderately correlated (r = 0.41). In both MANCOVA
models, the dependent variables were the 8 patient HRQOL subscales, independent variables
were physician or partner support and disease status, the moderating variable was the
disease status-by-support interaction term, and the control variables were patient gender,
age, race, education, years since diagnosis, vasculitis type, and health insurance status. For
each MANCOVA model, we inspected Wilks’ lambda for the interaction term as well as
disease status and support. If the Wilks’ lambda values were significant, we inspected
individual univariate analysis of covariance (ANCOVA) models to determine where
differences existed. To further describe the effects of medication-related support on each




The majority of participants (n = 228, Table 1) were female, white, and had a diagnosis of
ANCA-associated granulomatous vasculitis. On average, participants were middle-aged, had
completed some college education, and had been living with vasculitis for 6.4 years.
Twenty-eight percent were experiencing a relapse or flare at the time of the baseline survey.
Patients in both relapse and remission reported moderate amounts of support from their
physicians (mean = 2.1) and partners (mean = 2.1). Patients in remission reported more
education than relapsing patients (chi-square2 = 7.31, p = 0.03) and were more likely to have
a diagnosis of ANCA-associated granulomatous vasculitis (chi-square4 = 12.60, p = 0.01).
HRQOL of patients in relapse and remission
Figure 1 presents the norm-based HRQOL scores for vasculitis patients experiencing a
relapse, patients in remission, and the 1998 general US population aged 55–64 years.
Relapsing patients scored significantly worse than patients in remission on all HRQOL
subscales, with the exception of physical role limitations (Table 2).
Effect of physician medication-related support and disease status on HRQOL
The Wilks’ lambda for the disease status-by-physician support interaction term was
insignificant (lambda = 0.48; p = 0.87), indicating that physician support did not
differentially affect HRQOL for those experiencing a relapse compared to those in
remission. In a main-effects model without the interaction term, relapsing disease status
(lambda = 2.76; p < 0.01) and less physician support (lambda = 2.21; p = 0.03) were
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statistically significant predictors of lower HRQOL. The 8 ANCOVA models (Table 3)
revealed that relapsing disease status was a significant predictor of worse health for every
HRQOL dimension except physical role limitations. Higher physician support was a
significant predictor of better health for all HRQOL dimensions except bodily pain and
energy. One control variable, gender, also strongly influenced HRQOL; female patients
reported lower HRQOL than male patients for 6 of 8 dimensions.
To investigate the nature of the physician support-by-disease status interaction term, we
estimated the slope for the effect of physician support on each HRQOL dimension for those
in relapse and remission. As Table 4 shows, the slope for physician support was greater for
relapsing patients for every dimension of HRQOL except social functioning. The 95%
confidence intervals were significant for 4 of 8 HRQOL dimensions for relapsing patients,
but for only one of 8 dimensions for patients in remission. Regarding interpretation, the
slope for the effect of physician support on physical functioning was 4.23 for patients in
relapse and 1.95 for patients in remission. This means that for every 1-point increase in
physician support, patients experiencing a relapse reported a 4.23-point increase in physical
functioning, whereas patients in remission reported only a 1.95-point increase in physical
functioning.
Effect of partner medication-related support and disease status on HRQOL
In the MANCOVA model that explored whether disease status moderated the effect of
partner support on patient HRQOL, the disease status-by-partner support interaction term
was not significant (lambda = 1.51; p = 0.16). In the model without the interaction term,
relapsing disease status (lambda = 2.06; p = 0.04) and less partner support (lambda = 2.35; p
= 0.02) were both statistically significant predictors of lower HRQOL. Individual ANCOVA
models revealed that relapsing disease status was significantly associated with 4 of 8
HRQOL dimensions, including more bodily pain, worse general health, worse social
functioning, and worse mental health. More partner support was significantly associated
with better HRQOL for 6 of 8 dimensions (Table 5); support was not associated with bodily
pain or vitality.
Again, we estimated the slopes for the effect of partner support on each HRQOL dimension
for those in relapse and remission (Table 4). The slope for partner support was greater for
relapsing patients for every dimension of HRQOL, meaning that the benefit to HRQOL due
to increasing partner support was consistently greater for relapsing patients than patients in
remission. The 95% confidence intervals were significant for 5 of 8 HRQOL dimensions for
relapsing patients and 3 of 8 dimensions for patients in remission. The largest slope
difference was for emotional role limitations: for every 1-point increase in partner support,
relapsing patients experienced a 10.86-point improvement in emotional role limitations,
whereas patients in remission experienced only a 3.46-point improvement.
DISCUSSION
Similar to previous studies4,5,6,7,8,9,10,11,12, our results indicate that vasculitis has negative
effects on patients’ physical and mental quality of life. Vasculitis patients scored lower than
the general US population (ages 55–64 yrs) on every HRQOL dimension. Further, compared
to patients in remission, relapsing patients reported significantly worse quality of life on all
physical and mental health dimensions except physical role limitations, which trended
toward significance. Relapses exacted a physical and mental toll on patients’ HRQOL over
and above what was experienced during remission.
Our results are similar to those of Linde and colleagues28, who found that patients with
rheumatoid arthritis with higher physician-rated disease activity reported statistically
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significant reductions in HRQOL compared to patients in remission and to the general US
population. In contrast, a review article by McElhone and associates29 concluded that the
correlation between physician-rated disease activity and HRQOL was weak or nonexistent
for patients with systemic lupus erythematosus. Similarly, Koutantji and colleagues8 found
no association between disease activity and HRQOL for patients with primary systemic
vasculitis. Thus, findings regarding the effect of disease activity on HRQOL remain mixed.
Support from physicians and partners was associated with better physical and mental health,
as found with previous studies15,16,17,18,19,20,21,22,23,24. However, support was not
associated with bodily pain or vitality. One might expect that medication-related support
would have a greater influence on pain and vitality because improved adherence to
medication might be related to a decrease in symptoms. It appears that support from
physicians and partners in this study had a weaker effect on physical symptoms than on a
general sense of well-being that arose from perceiving others as caring. Thus, medication-
related support may have yielded stronger associations with more general outcomes, such as
physical and social functioning, than on more specific physical symptoms. The data from
this study, however, cannot confirm that interpretation.
We did not find evidence that relapsing disease status moderated the effect of social support
on HRQOL, but it is difficult to put these results into a broader context because there has
been little work in this area. One study by Bae and colleagues30 found that social support
was more beneficial for lupus patients’ physical functioning during periods of lower disease
activity in contrast to greater disease activity. The discrepancy between our results and those
of Bae, et al may be due to the use of a patient-reported, rather than a physician-reported,
measure of disease activity. Because patients have access to information about their own
illness experiences that may be difficult for physicians or other observers to incorporate into
their disease activity ratings, observing patients’ personal experiences about how their
illness affects them seems necessary to predict HRQOL. Ideally, future research will
incorporate both patient and physician-reported disease activity measures to determine
whether each measure offers unique information in the prediction of HRQOL.
Although the pattern of slopes for physician and partner support were consistent with
moderation, the disease status-by-support interaction terms in the multivariate models were
not significant. One possible explanation is that relapsing disease status was so strongly
associated with HRQOL that it did not leave much additional variation for the interaction
term to explain. If we had more relapsing patients in our sample, we may have been able to
detect a significant interaction term. Future studies should attempt to recruit a larger sample
of relapsing patients and compare them to patients in remission and healthy controls to
determine whether the trends seen in our results are replicable and statistically significant.
Our results suggest that gender may act as a moderator of the relationship between support
and HRQOL, although we did not formally test this interaction due to small cell sizes that
resulted from further dividing the sample. As documented by Revenson and colleagues31,
there are substantial differences in how men and women cope with chronic illness. Thus,
research exploring whether women benefit more from support during a relapse than men is
warranted.
Generalizability is limited by our sample’s lack of diversity, which was predominantly
older, female, and white. Because the study surveys were completed online, our sample may
have been more motivated, better educated, and had greater resources than the general
vasculitis population, possibly contributing to the lack of a significant interaction between
support and disease status. Additionally, self-reported diagnoses of vasculitis may not be
completely accurate. For our analyses, we grouped multiple types of vasculitis patients
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together (e.g., Takayasu’s arteritis, Churg-Strauss syndrome, microscopic polyangiitis) in
order to compare them to ANCA-associated granulomatous vasculitis. It is possible that this
grouping masked differences in quality of life attributable to permanent disease damage,
which can differ for different types of vasculitis32. Further, our ability to assert a causal
relationship between support and HRQOL is limited because we were unable to control for
baseline HRQOL. Finally, because we combined “not applicable” responses with “does not
do this” responses for our social support measures, we cannot differentiate between people
who thought support was unimportant/unnecessary from those who thought support
mattered but were not receiving it. More sophisticated measures of support that include a
response category such as “I do not need this type of support” could be used in the future to
make distinctions between those who want but are not receiving support and those who do
not want support.
Our findings indicate that vasculitis negatively affects patients across multiple quality of life
domains and that relapses further compromise patients’ physical and mental functioning.
Social support from physicians and partners helped reduce the negative impact of vasculitis
on HRQOL regardless of where patients were in the cycle of relapse and remission. Because
social support was not associated with improvements in pain or vitality, addressing
treatment options for physical symptoms during office visits may benefit patients more than
simply offering medication-related support. Even though physicians have less frequent
contact with patients than partners, physician support positively affected patients’ physical
and mental quality of life. Thus, conveying support to the patient during office visits may
exert a lasting, positive effect. Replication of our results with larger samples and more
general support measures is necessary before concluding that social support is equally
beneficial for patients during relapse and remission.
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Norm-based health related quality of life scores for patients with vasculitis in relapse (n =
64) and in remission (n = 164) and a 1998 general US population, ages 55–64 years27. PF:
physical functioning, RP: physical role limitations, BP: bodily pain, GH: general health, VT:
vitality, SF: social functioning, RE: emotional role limitations, MH: mental health.
*Significant Bonferroni-corrected t test comparing patients in relapse to patients in
remission (p < 0.00625).
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Table 1





Mean ± SD or % Range
Demographic data
 Age, yrs 48.9 ± 12.8 51.9 ± 13.4 20.0–82.0
 Female, % 75.0 67.7
 White, % 89.1 92.1
 Education, %*
  High school or less 18.6 17.3 4.0–22.0 yrs
  Some college 46.8 50.0
  College graduate or more 30.7 32.7
 Has a spouse/partner, % 76.6 83.5
 Health insurance, % 95.3 92.6
Clinical data
 Disease type*, %
  ANCA-associated vasculitis 51.6 62.2
  Churg-Strauss syndrome 10.9 13.4
  Microscopic polyangiitis 3.1 9.8
  Takayasu arteritis 7.8 3.7
  Other 26.6 11.0
 Years with disease 5.2 ± 5.7 6.9 ± 6.3 0.5–36.5
Support
 Physician support
† 2.0 ± 0.7 2.1 ± 0.7 1.0–4.0
 Partner support
† 2.0 ± 0.7 2.2 ± 0.8 1.0–4.0
*
Significant chi-sauare test comparing relapse and remission groups (p < 0.05).
†
Physician and partner support ranges from 1 to 4, higher values indicating greater levels of medication-related support.













CARPENTER et al. Page 12
Table 2
Means, standard deviations, and t test statistics comparing health-related quality of life27 of vasculitis patients





Mean ± SD t test p
Physical functioning (PF) 36.38 ± 12.2 41.63 ± 11.9 2.96 0.0034*
Physical role limitations (RP) 34.58 ± 10.1 39.09 ± 11.7 2.72 0.0070
Bodily pain (BP) 40.35 ± 11.0 47.92 ± 10.6 4.77 < 0.0001*
General health (GH) 33.57 ± 7.0 37.56 ± 7.3 3.77 0.0002*
Vitality (VT) 37.18 ± 10.7 42.35 ± 11.8 3.05 0.0026*
Social functioning (SF) 35.34 ± 12.0 43.40 ± 12.0 4.55 0.0001*
Emotional role limitations (RE) 38.66 ± 14.3 44.35 ± 13.1 2.81 0.0055*
Mental health (MH) 41.50 ± 12.4 47.53 ± 11.1 3.57 0.0004*
*
Significant Bonferroni-corrected t test (p < 0.00625).
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Table 4
Slope estimates for the effect of physician and partner support on health-related quality of life for patients













Physical functioning 4.23 (0.39, 8.07) 1.95 (−0.58, 4.48) 5.49 (1.05, 9.92) 1.32 (−1.08, 3.71)
Physical role limitations 3.56 (−0.33, 7.45) 2.16 (−0.41, 4.72) 4.76 (0.37, 9.14) 2.43 (0.05, 4.80)
Bodily pain 3.12 (−0.61, 6.85) 0.92 (−1.54, 3.38) 2.47 (−1.89, 6.83) 1.32 (−1.04, 3.67)
General health 2.62 (0.10, 5.14) 1.46 (−0.20, 3.12) 3.42 (0.36, 6.48) 1.07 (−0.58, 2.72)
Vitality 2.75 (−1.29, 6.79) 1.28 (−1.38, 3.94) 3.15 (−1.57, 7.86) 1.19 (−1.36, 3.37)
Social functioning 3.80 (−0.37, 7.96) 4.07 (1.33, 6.82) 3.70 (−1.00, 8.40) 2.60 (0.06, 5.14)
Emotional role limitations 4.80 (0.15, 9.44) 2.60 (−0.46, 5.66) 10.86 (5.59, 16.13) 3.46 (0.61, 6.31)
Mental health 4.11 (0.09, 8.12) 2.84 (0.19, 5.48) 4.61 (0.04, 9.18) 2.10 (−0.37, 4.57)
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